NCT04782258: A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
- State
- Under way
- Phase
- Phase 3
- People
- 20 planned
- Started
- 23 Jan 2023
- Primary completion
- 28 Dec 2028
- Arms
- Tolvaptan Suspension, Tolvaptan Tablets
- Results
- None posted
- 4 Mar 2021: Trial registered
- 23 Jan 2023: Trial started